Premium
Evaluation of monoclonal antibodies against Plasmodium vivax sporozoites for ELISA development
Author(s) -
WIRTZ R. A.,
CHAROENVIT Y.,
BURKOT T. R.,
ESSER K. M.,
BEAUDOIN R. L.,
COLLINS W. E.,
ANDRE R. G.
Publication year - 1991
Publication title -
medical and veterinary entomology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 82
eISSN - 1365-2915
pISSN - 0269-283X
DOI - 10.1111/j.1365-2915.1991.tb00515.x
Subject(s) - monoclonal antibody , biology , plasmodium vivax , virology , antibody , immunofluorescence , epitope , heterologous , microbiology and biotechnology , anopheles gambiae , immunoassay , malaria , plasmodium falciparum , immunology , biochemistry , gene
. Nine monoclonal antibodies (MAbs) developed against Plasmodium vivax (Grassi & Feletti) salivary gland sporozoites were evaluated for use in an enzyme‐linked immunosorbent assay (ELISA), using sporozoites developed in Anopheles dims Peyton & Harrison An.gambiae Giles and An.maculatus Theobald. Four of the antibodies were unsuitable due to the low sensitivity of the resulting assays or the requirement for high concentrations of capture antibody. An additional two MAbs were rejected because they resulted in assays with high background absorbance, attributed to self‐binding. Of the three remaining MAbs, the use of Navy vivax sporozoite (NVS) 3 resulted in an ELISA with the highest sensitivity and the lowest concentration requirement for capture antibody. Assay sensitivity varied with sporozoite strain indicating possible quantitative epitope heterogeneity. None of the MAbs cross‐reacted with the heterologous sporozoites tested by immunofluorescence antibody assay (IFA). The IFA activity was not an indicator of ELISA sensitivity. The use of MAb NVS 3 in a standardized ELISA method resulted in an assay 10 times more sensitive than reported previously for P. vivax sporozoites, with a detection limit of fewer than 100 sporozoites per mosquito.